Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
Figure 2
Changes in left ventricular mass index (LVMI; (a)) and N-terminal brain natriuretic peptide (NT-proBNP; (b)) in patients treated with bromocriptine (BEC) and placebo (PBO). LVMI decreased in the BEC group and increased in the PBO group. A similar pattern of changes was observed for NT-proBNP which decreased in the BEC group and increased in the PBO group. Changes in left ventricle mass index (Δ LVMI; (c)) were more significant in BEC than in PBO group independently if blood pressure was within (<140/90 mmHg) or not within normal limits.
